share_log

康方生物：與正大天晴進行有關派安普利（PD-1單抗(AK105)）臨床試驗的持續關連交易物料及服務總採購協議超出2023年年度上限

AKESO: EXCEEDED 2023 ANNUAL CAPS FOR CONTINUING CONNECTED TRANSACTIONS MASTER MATERIALS AND SERVICES PROCUREMENT AGREEMENT WITH CHIA TAI TIANQING IN RELATION TO CLINICAL TRIAL OF PENPULIMAB (PD-1 MONOCLONAL ANTIBODY, AK105)

Hong Kong Stock Exchange ·  Apr 28 07:11
Summary by Moomoo AI
康方生物科技（開曼）有限公司（「康方生物」）於2024年4月28日宣布，其附屬公司天晴康方在2023財年的實際購買成本約為人民幣106.8百萬元，超出年度上限約人民幣37.8百萬元。該超支主要是由於派安普利（PD-1單抗AK105）臨床試驗的臨床服務及物料需求高於預期。公司已採取措施加強內部監控，以防止未來類似情況發生。根據上市規則，該交易需遵守申報、公告及年度審核規定，但可豁免遵守通函、獨立財務意見及獨立股東批准的規定。康方生物表示，若2024年度的年度上限需調整，將嚴格遵守上市規則。
康方生物科技（開曼）有限公司（「康方生物」）於2024年4月28日宣布，其附屬公司天晴康方在2023財年的實際購買成本約為人民幣106.8百萬元，超出年度上限約人民幣37.8百萬元。該超支主要是由於派安普利（PD-1單抗AK105）臨床試驗的臨床服務及物料需求高於預期。公司已採取措施加強內部監控，以防止未來類似情況發生。根據上市規則，該交易需遵守申報、公告及年度審核規定，但可豁免遵守通函、獨立財務意見及獨立股東批准的規定。康方生物表示，若2024年度的年度上限需調整，將嚴格遵守上市規則。
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) announced on 28 April 2024 that the actual purchase cost of its subsidiary Tianqing Kangfang in fiscal 2023 was approximately RMB106.8 million, exceeding the annual cap of approximately RMB37.8 million. The overspend was primarily due to higher than expected demand for clinical services and materials in the Piampoli (PD-1 single anti-AK105) clinical trial. The company has taken steps to strengthen internal controls to prevent similar situations from happening in the future. Under the Listing Rules, the transaction is subject to the requirements of declarations, announcements and annual audits, but is exempt from compliance with Circulars, Independent Financial Opinions and Independent Shareholder Approvals. Kangfang Bio said that listing rules will be strictly adhered to if the annual cap is adjusted in 2024.
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) announced on 28 April 2024 that the actual purchase cost of its subsidiary Tianqing Kangfang in fiscal 2023 was approximately RMB106.8 million, exceeding the annual cap of approximately RMB37.8 million. The overspend was primarily due to higher than expected demand for clinical services and materials in the Piampoli (PD-1 single anti-AK105) clinical trial. The company has taken steps to strengthen internal controls to prevent similar situations from happening in the future. Under the Listing Rules, the transaction is subject to the requirements of declarations, announcements and annual audits, but is exempt from compliance with Circulars, Independent Financial Opinions and Independent Shareholder Approvals. Kangfang Bio said that listing rules will be strictly adhered to if the annual cap is adjusted in 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more